tiprankstipranks
Trending News
More News >
Polynovo Limited (AU:PNV)
ASX:PNV

Polynovo (PNV) AI Stock Analysis

Compare
60 Followers

Top Page

AU

Polynovo

(Sydney:PNV)

Rating:58Neutral
Price Target:
AU$1.50
▲(11.94%Upside)
Polynovo Limited shows promise with strong revenue growth and improved financial health, but the high P/E ratio suggests overvaluation. Technical indicators are mixed, with short-term caution advised. The lack of earnings call and corporate events data limits additional insights.

Polynovo (PNV) vs. iShares MSCI Australia ETF (EWA)

Polynovo Business Overview & Revenue Model

Company DescriptionPolyNovo Limited develops medical devices in the United States, Australia, New Zealand, the United Kingdom, Ireland, Singapore, and internationally. The company offers NovoSorb Biodegradable Temporising Matrix, which is used in a fully debrided clean surgical wound to physiologically close the wound. It is also developing hernia devices for hernia repair and tissue reinforcement products; NovoSorb Dermal Beta Cell Implant to host pancreatic islets in the skin; and NovoSorb drug elution depots. The company was formerly known as Calzada Limited and changed its name to PolyNovo Limited in November 2014. PolyNovo Limited was incorporated in 1998 and is headquartered in Port Melbourne, Australia.
How the Company Makes MoneyPolyNovo Limited generates revenue through the sale of its medical devices, particularly the NovoSorb BTM, to hospitals, clinics, and healthcare providers worldwide. The company also engages in strategic partnerships and collaborations with distributors and medical organizations to expand its market reach. Additionally, PolyNovo invests in expanding its product portfolio and exploring new applications of its NovoSorb technology, which could lead to future revenue streams. Key factors contributing to its earnings include product adoption rates, regulatory approvals, and the company's ability to penetrate new markets.

Polynovo Financial Statement Overview

Summary
Polynovo Limited exhibits promising growth with strong revenue increase and a return to profitability. The company has shown improvements in financial health, but there is room for operational efficiency and better cash flow conversion.
Income Statement
75
Positive
Polynovo Limited has shown strong revenue growth with a notable increase from $65.24M in 2023 to $103.19M in 2024. The company turned profitable with a net income of $5.26M in 2024, demonstrating a positive net profit margin. The gross profit margin improved significantly, indicative of better cost management. However, the EBIT and EBITDA margins, although improved, remain relatively low, suggesting room for operational efficiency improvements.
Balance Sheet
68
Positive
The company maintains a solid equity position with a strong equity ratio of approximately 66.36% in 2024, which indicates financial stability. The debt-to-equity ratio decreased over the years, reflecting prudent financial management. However, the return on equity is moderate, suggesting that while the company is financially stable, it could improve its efficiency in generating profits from its equity base.
Cash Flow
62
Positive
Polynovo's cash flow situation has improved, with a positive operating cash flow of $3.68M in 2024 compared to negative figures in previous years. Free cash flow turned positive, indicating better cash management. However, the free cash flow to net income ratio is relatively low, suggesting that the conversion of net income to free cash flow could be enhanced.
Breakdown
TTMJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income StatementTotal Revenue
115.58M103.19M65.24M41.44M29.16M22.16M
Gross Profit
72.83M97.71M19.33M16.23M7.83M5.01M
EBIT
3.39M1.16M-6.19M-256.66K-3.15M-4.14M
EBITDA
9.38M5.17M-2.71M961.93K-3.41M-3.21M
Net Income Common Stockholders
5.91M5.26M-4.92M-1.19M-4.61M-4.19M
Balance SheetCash, Cash Equivalents and Short-Term Investments
8.19M45.96M46.90M6.15M7.74M11.70M
Total Assets
29.59M108.72M92.62M34.97M38.34M37.86M
Total Debt
2.42M15.38M16.04M10.99M10.00M10.03M
Net Debt
-5.72M-30.53M-30.80M4.89M2.31M-1.62M
Total Liabilities
5.07M36.60M27.24M17.26M15.99M14.04M
Stockholders Equity
24.52M72.12M65.38M17.72M22.35M23.81M
Cash FlowFree Cash Flow
-16.35M786.00K-7.46M-2.55M-3.82M-9.27M
Operating Cash Flow
-9.44M3.68M-5.93M-2.06M-248.74K-402.56K
Investing Cash Flow
-5.48M-1.49M-1.53M5.86M-3.57M-8.87M
Financing Cash Flow
-3.97M-3.17M48.06M-5.39M-70.37K7.03M

Polynovo Technical Analysis

Technical Analysis Sentiment
Positive
Last Price1.34
Price Trends
50DMA
1.25
Positive
100DMA
1.48
Negative
200DMA
1.86
Negative
Market Momentum
MACD
<0.01
Positive
RSI
52.81
Neutral
STOCH
68.83
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:PNV, the sentiment is Positive. The current price of 1.34 is below the 20-day moving average (MA) of 1.36, above the 50-day MA of 1.25, and below the 200-day MA of 1.86, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 52.81 is Neutral, neither overbought nor oversold. The STOCH value of 68.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:PNV.

Polynovo Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
AUPNV
58
Neutral
$929.18M156.408.30%39.19%273.91%
54
Neutral
$5.37B3.35-45.10%2.79%16.77%-0.01%
$82.91M-15.86%
AUARX
54
Neutral
AU$179.35M-4.06%15.90%8.52%
AUEMV
48
Neutral
AU$152.22M-58.61%-74.88%
AUCYC
44
Neutral
AU$118.92M-35.20%4.68%-155.42%
AU4DX
42
Neutral
AU$139.66M-52.37%471.29%-4.58%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:PNV
Polynovo
1.35
-0.90
-39.96%
SOMNF
Somnomed Limited
0.42
0.24
133.33%
AU:CYC
Cyclopharm Limited
1.07
-0.51
-32.28%
AU:ARX
Aroa Biosurgery Ltd
0.54
-0.07
-11.48%
AU:EMV
EMvision Medical Devices Ltd.
1.78
-0.16
-8.25%
AU:4DX
4DMedical Ltd
0.30
-0.36
-54.55%

Polynovo Corporate Events

Polynovo Announces Changes in Shareholder Structure
May 21, 2025

Polynovo Limited has announced a significant change in its shareholder structure, with various entities, including State Street Bank and Trust Company and its subsidiaries, becoming substantial holders. This development indicates a shift in the company’s ownership dynamics, potentially impacting its strategic decisions and market positioning. The involvement of major financial institutions as substantial holders could influence Polynovo’s future operations and stakeholder engagements.

The most recent analyst rating on (AU:PNV) stock is a Buy with a A$2.50 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.

PolyNovo Releases May 2025 Investor Update Webcast Recording
May 16, 2025

PolyNovo has released a recording of its May 2025 Investor Update Webcast for shareholders and interested parties who missed the live event. This announcement underscores PolyNovo’s commitment to transparency and stakeholder engagement, potentially strengthening its market position and investor relations.

The most recent analyst rating on (AU:PNV) stock is a Buy with a A$2.50 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.

PolyNovo’s NovoSorb BTM Shows Breakthrough Results in Type 1 Diabetes Cell Therapy
May 13, 2025

PolyNovo announced positive results from a ‘first in human’ study using its NovoSorb BTM technology for cell therapies in treating Type 1 diabetes. The study, presented by Professor Toby Coates, demonstrated the survival and function of human pancreatic islets transplanted into a new site within the skin, offering a promising alternative to the current standard of care. This breakthrough suggests significant potential for NovoSorb in the cell therapy market, potentially creating a new business segment for PolyNovo. The company is in discussions to accelerate research and development in this space, which is projected to reach USD $34 billion by 2034.

The most recent analyst rating on (AU:PNV) stock is a Buy with a A$2.50 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.

PolyNovo Secures TGA Clearance for NovoSorb MTX in Australia
May 12, 2025

PolyNovo Limited has achieved a significant commercial milestone with the Therapeutic Goods Administration (TGA) clearance of its NovoSorb MTX (4 mm and 6 mm) products in Australia. This clearance allows the products to be marketed and sold, providing healthcare professionals with versatile options for managing soft tissue defects. The NovoSorb MTX is designed to support natural wound healing, particularly for highly exudative wounds or those with uneven wound beds, and addresses clinician demand for products without a sealing membrane. This development enhances PolyNovo’s industry positioning by expanding its product offerings and meeting the needs of plastic surgeons and other healthcare providers.

PolyNovo Highlights Strategic Focus at Macquarie Australia Conference
May 7, 2025

PolyNovo Limited’s presentation at the Macquarie Australia Conference highlights the company’s ongoing commitment to innovation in wound care technology. While the presentation includes forward-looking statements subject to change, it underscores the company’s strategic focus on expanding its market presence and enhancing its product offerings, which could have significant implications for its stakeholders.

PolyNovo to Host Investor Update on Strategic Growth and Financial Outlook
May 1, 2025

PolyNovo Limited announced an upcoming investor update webcast scheduled for May 16, where it will discuss its financial performance, future outlook, cash and capital adequacy, and growth strategies, including market expansion into China and Japan and the launch of NovoSorb MTX. This update is significant for stakeholders as it highlights PolyNovo’s strategic initiatives to enhance its market position and expand its product offerings, potentially impacting its operations and industry standing.

JPMorgan Chase Reduces Stake in Polynovo Limited
Apr 22, 2025

JPMorgan Chase & Co. and its affiliates have reduced their voting power in Polynovo Limited from 9.06% to 7.98%, as detailed in a recent notice of change of interests. This adjustment in voting power may influence the company’s shareholder dynamics and could have implications for its governance and decision-making processes.

JPMorgan Increases Stake in Polynovo Limited
Apr 16, 2025

Polynovo Limited, a company in the medical device industry, has seen a change in the substantial holding of its shares by JPMorgan Chase & Co. and its affiliates. The voting power of JPMorgan has increased from 7.53% to 9.06% as of April 14, 2025, indicating a significant shift in shareholder interest and potential influence over company decisions.

PolyNovo Announces Change in Company Secretary
Apr 14, 2025

PolyNovo Limited has announced the resignation of Mr. Lior Harel from his role as General Counsel and Company Secretary, effective April 15, 2025, as he pursues other opportunities. The responsibilities will be temporarily taken over by CFO Jan-Marcel Gielen until a replacement is appointed, indicating a seamless transition in leadership roles within the company.

JPMorgan Chase Increases Stake in Polynovo Limited
Apr 11, 2025

Polynovo Limited has experienced a change in the interests of its substantial holder, JPMorgan Chase & Co. and its affiliates, who have increased their voting power from 6.30% to 7.53%. This change reflects a significant shift in the company’s shareholder structure, potentially impacting its market positioning and stakeholder relations.

State Street Corporation Ceases Substantial Holding in Polynovo Limited
Apr 11, 2025

Polynovo Limited has announced that State Street Corporation and its subsidiaries have ceased to be substantial holders in the company as of April 9, 2025. This change in substantial holding could impact Polynovo’s shareholder structure and influence its market position, as State Street’s exit might affect investor perceptions and future investment strategies.

PolyNovo Achieves Record Sales and Revenue in March 2025
Apr 9, 2025

PolyNovo Limited announced record-breaking unaudited sales and revenue figures for March 2025, with monthly sales reaching A$11.9 million and total revenue hitting A$12.4 million. The company experienced significant growth across multiple regions, particularly in the United States and the United Kingdom, driven by increased account acquisition and the expanded use of their NovoSorb products. The strong financial performance and cash reserves position PolyNovo well to continue its strategic initiatives, including the completion of a new manufacturing facility and R&D innovation center.

Polynovo Limited Announces Change in Substantial Shareholdings
Apr 7, 2025

Polynovo Limited has announced a significant change in its shareholder structure, with State Street Bank and Trust Company and its associates becoming substantial holders. This development indicates a strategic shift in the company’s ownership, potentially impacting its future governance and market strategies.

FIL Limited Increases Stake in Polynovo Limited
Apr 7, 2025

Polynovo Limited has experienced a change in the interests of its substantial holder, FIL Limited, which has increased its voting power from 8.63% to 9.65% as of April 3, 2025. This increase in voting power reflects FIL Limited’s ongoing investment in Polynovo, potentially impacting the company’s market positioning and indicating a vote of confidence from a significant shareholder.

PolyNovo Secures Key Regulatory Approvals for NovoSorb MTX Expansion
Mar 19, 2025

PolyNovo Limited has achieved significant regulatory milestones for its NovoSorb MTX product line, receiving FDA 510k clearance in the U.S. for up to 6 mm thickness with new indications for tunneled/undermined wounds. This clearance is expected to enhance the product’s versatility in managing deep soft tissue defects and expand its use in plastic and reconstructive surgery. Additionally, NovoSorb MTX with a 2 mm thickness has been approved for marketing in Australia and for importation in India, broadening its market presence. These developments are poised to strengthen PolyNovo’s position in the medical technology industry and provide new opportunities for growth, particularly benefiting plastic surgeons and healthcare professionals.

FIL Limited Increases Stake in Polynovo Limited
Mar 14, 2025

Polynovo Limited has experienced a change in the interests of a substantial holder, FIL Limited, which has increased its voting power from 6.48% to 7.56%. This change reflects FIL Limited’s active trading in Polynovo’s common stock, with several buy and sell transactions occurring between February 20, 2025, and March 5, 2025. The increase in voting power suggests a strengthened position for FIL Limited within Polynovo, potentially impacting the company’s shareholder dynamics and strategic decisions.

PolyNovo Announces CEO Change and Strategic Leadership Transition
Mar 10, 2025

PolyNovo Limited has announced a change in leadership with the departure of CEO Mr. Swami Raote, effective June 10, 2025. Dr. Robyn Elliott, a non-executive director with extensive experience in business development and operational strategy, will serve as Acting CEO until a permanent replacement is found. This leadership change is aimed at continuing the company’s growth and transformation, with an executive search for a new CEO underway. The Board is also reviewing its structure and composition to ensure effective governance and succession planning.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.